MX2019004905A - Conjugados de oligosacaridos-proteinas. - Google Patents
Conjugados de oligosacaridos-proteinas.Info
- Publication number
- MX2019004905A MX2019004905A MX2019004905A MX2019004905A MX2019004905A MX 2019004905 A MX2019004905 A MX 2019004905A MX 2019004905 A MX2019004905 A MX 2019004905A MX 2019004905 A MX2019004905 A MX 2019004905A MX 2019004905 A MX2019004905 A MX 2019004905A
- Authority
- MX
- Mexico
- Prior art keywords
- oligosaccharide
- protein conjugates
- conjugates
- protein
- formulae
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
En el presente documento se proporcionan conjugados que comprenden una proteína y un oligosacárido de una de las fórmulas I-VI. También se proporcionan composiciones farmacéuticas que comprenden estos conjugados. Además, se proporcionan procedimientos para tratar un trastorno por depósito lisosomal en un mamífero con la administración de un conjugado de oligosacáridos-glicoproteínas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12285108P | 2008-12-16 | 2008-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019004905A true MX2019004905A (es) | 2020-11-12 |
Family
ID=42138937
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015002855A MX364498B (es) | 2008-12-16 | 2009-12-11 | Conjugados de oligosacáridos-protenías. |
MX2011006347A MX2011006347A (es) | 2008-12-16 | 2009-12-11 | Conjugados de oligosacaridos-proteinas. |
MX2019004905A MX2019004905A (es) | 2008-12-16 | 2011-06-14 | Conjugados de oligosacaridos-proteinas. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015002855A MX364498B (es) | 2008-12-16 | 2009-12-11 | Conjugados de oligosacáridos-protenías. |
MX2011006347A MX2011006347A (es) | 2008-12-16 | 2009-12-11 | Conjugados de oligosacaridos-proteinas. |
Country Status (21)
Country | Link |
---|---|
US (5) | US8835614B2 (es) |
EP (5) | EP3608330B1 (es) |
JP (6) | JP5658167B2 (es) |
CN (5) | CN103432566A (es) |
BR (2) | BRPI0923047B8 (es) |
CA (2) | CA2747230C (es) |
CY (1) | CY1121860T1 (es) |
DK (3) | DK2465542T3 (es) |
ES (3) | ES2534056T3 (es) |
HK (2) | HK1171697A1 (es) |
HR (2) | HRP20150340T1 (es) |
HU (2) | HUE044381T2 (es) |
IL (5) | IL213595B (es) |
LT (1) | LT2889043T (es) |
MX (3) | MX364498B (es) |
PL (2) | PL2465542T3 (es) |
PT (2) | PT2465542E (es) |
SI (2) | SI2465542T1 (es) |
SM (1) | SMT201500082B (es) |
TR (1) | TR201909909T4 (es) |
WO (1) | WO2010075010A2 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723296B2 (en) * | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
DK2457920T3 (en) | 2007-01-18 | 2018-01-22 | Genzyme Corp | Oligosaccharides comprising an amino oxy group and conjugates thereof |
EP3608330B1 (en) * | 2008-12-16 | 2022-11-09 | Genzyme Corporation | Synthetic intermediates for preparing oligosaccharide-protein conjugates |
RU2569744C2 (ru) | 2009-08-28 | 2015-11-27 | Маунт Синай Скул Оф Медсин | Ферментная заместительная терапия с увеличением дозы для лечения недостаточности кислой сфингомиелиназы |
KR20140037082A (ko) | 2011-04-22 | 2014-03-26 | 겐자임 코포레이션 | 가속 가공으로 변형된 산 알파 글루코시다제 |
EP2793922B1 (en) * | 2011-12-23 | 2019-10-30 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
WO2013176239A1 (ja) * | 2012-05-24 | 2013-11-28 | 国立大学法人 東京大学 | 酸化オリゴ糖で架橋したゲル材料 |
ES2967620T3 (es) * | 2014-09-30 | 2024-05-03 | Amicus Therapeutics Inc | Alfa-glucosidasa ácida altamente potente con carbohidratos potenciados |
AU2016232149B2 (en) | 2015-03-17 | 2021-09-23 | eleva GmbH | Glycosylated lysosomal proteins, method of production and uses |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
BR112018013151A2 (pt) | 2015-12-30 | 2018-12-18 | Amicus Therapeutics Inc | alfa-glicosidase ácida aumentada para o tratamento da doença de pompe |
US10227577B2 (en) | 2016-03-30 | 2019-03-12 | Amicus Therapeutics, Inc. | Method for selection of high M6P recombinant proteins |
US10512676B2 (en) | 2016-03-30 | 2019-12-24 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
JP6996676B2 (ja) * | 2016-03-30 | 2022-02-04 | 国立研究開発法人農業・食品産業技術総合研究機構 | マンノース-6-リン酸基含有糖蛋白質の製造方法、及び蛍光基結合型マンノース-6-リン酸基含有糖蛋白質の細胞内分布を検出する方法 |
WO2017175082A1 (en) * | 2016-04-05 | 2017-10-12 | Gsk Vaccines S.R.L. | Immunogenic compositions |
CN106432371A (zh) * | 2016-10-31 | 2017-02-22 | 中国人民解放军第二军医大学 | β‑1,2‑D‑寡聚甘露糖蛋白缀合物及其制备方法和应用 |
CN106366163A (zh) * | 2016-10-31 | 2017-02-01 | 中国人民解放军第二军医大学 | 一种β‑1,2‑D‑寡聚甘露糖肽‑蛋白缀合物及其制备方法和应用 |
EP3820473A4 (en) * | 2018-07-09 | 2022-05-11 | Merck Sharp & Dohme Corp. | ENZYMATIC SYNTHESIS OF 4'-ETHINYL NUCLEOSIDE ANALOGUES |
TW202142264A (zh) * | 2020-02-08 | 2021-11-16 | 美商健臻公司 | 治療龐貝氏症的組成物及方法 |
WO2021257409A1 (en) | 2020-06-14 | 2021-12-23 | Genzyme Corporation | Compositions and methods for treating late-onset pompe disease |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4701521A (en) | 1978-07-17 | 1987-10-20 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
US4749570A (en) | 1981-12-31 | 1988-06-07 | The Governors Of The University Of Alberta | Targeting conjugates of albumin and therapeutic agents |
US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
JPS5936691A (ja) * | 1982-08-24 | 1984-02-28 | Rikagaku Kenkyusho | 新規オリゴマンノシド及びその製造法 |
US5851991A (en) | 1987-08-31 | 1998-12-22 | The Regents Of The University Of California | Therapeutic use of the retinoblastoma susceptibility gene product |
US5066789A (en) | 1988-09-30 | 1991-11-19 | Neorx Corporation | Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages |
US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
IL93432A (en) | 1989-02-24 | 1994-02-27 | Johnson Mathey Inc | Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions |
US5206370A (en) | 1989-02-24 | 1993-04-27 | Johnson Matthey, Inc. | Certain pyridyl hydrazines and hydrazides useful for protein labeling |
US5179023A (en) | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
US5212298A (en) | 1989-08-16 | 1993-05-18 | Monsanto Company | Method for producing synthetic N-linked glycoconjugates |
US5280113A (en) | 1989-08-16 | 1994-01-18 | Monsanto Company | Method for producing synthetic N-linked glycoconjugates |
US5324663A (en) | 1990-02-14 | 1994-06-28 | The Regents Of The University Of Michigan | Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
US5583042A (en) | 1990-04-16 | 1996-12-10 | Neose Pharmaceuticals, Inc. | Apparatus for the synthesis of saccharide compositions |
US5312903A (en) * | 1990-06-01 | 1994-05-17 | E. I. Du Pont De Nemours And Company | Lysine-glycosylated recombinant interleukin-2 |
US5677440A (en) | 1990-07-16 | 1997-10-14 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
EP0513332A4 (en) | 1990-11-14 | 1993-03-17 | Cargill, Incorporated | Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins |
JPH06506217A (ja) | 1991-03-18 | 1994-07-14 | エンゾン,インコーポレーテッド | ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体 |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
UA41502C2 (uk) * | 1991-12-20 | 2001-09-17 | Ново Нордіск А/С | Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання |
US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
US6372716B1 (en) * | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
FR2721612B1 (fr) | 1994-06-23 | 1996-08-09 | Idm | Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications. |
US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
US5939401A (en) | 1994-12-09 | 1999-08-17 | Genzyme Corporation | Cationic amphiphile compositions for intracellular delivery of therapeutic molecules |
US5719131A (en) | 1994-12-09 | 1998-02-17 | Genzyme Corporation | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
US5948767A (en) | 1994-12-09 | 1999-09-07 | Genzyme Corporation | Cationic amphiphile/DNA complexes |
US5910487A (en) | 1994-12-09 | 1999-06-08 | Genzyme Corporation | Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
US5767099A (en) | 1994-12-09 | 1998-06-16 | Genzyme Corporation | Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules |
US5650096A (en) | 1994-12-09 | 1997-07-22 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5747471A (en) | 1994-12-09 | 1998-05-05 | Genzyme Corporation | Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules |
US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
US6492332B1 (en) | 1995-12-12 | 2002-12-10 | Omeros Corporation | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation |
US5811510A (en) | 1995-04-14 | 1998-09-22 | General Hospital Corporation | Biodegradable polyacetal polymers and methods for their formation and use |
US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
EP1983057A3 (en) | 1995-09-08 | 2009-01-07 | Genzyme Corporation | Improved AAV vectors for gene therapy |
WO1997010817A1 (en) | 1995-09-20 | 1997-03-27 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
US7141676B1 (en) | 1996-02-08 | 2006-11-28 | University Of Washington | Water soluble multi-biotin-containing compounds |
AU2341197A (en) * | 1996-03-21 | 1997-10-10 | Intercardia, Inc. | Solid phase lipoglycopeptide library, compositions and methods |
US5840702A (en) | 1996-03-22 | 1998-11-24 | Uab Research Foundation | Cystic fibrosis treatment |
US5935936A (en) | 1996-06-03 | 1999-08-10 | Genzyme Corporation | Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules |
AUPO190596A0 (en) | 1996-08-26 | 1996-09-19 | Alchemia Pty Ltd | Oligosaccharide synthesis |
EP2374876B1 (en) | 1996-09-13 | 2016-04-13 | Shire Human Genetic Therapies, Inc. | Purification process of alpha-galactosidase A |
US5861397A (en) | 1996-10-03 | 1999-01-19 | Vical Incorporated | Piperazine based cytofectins |
ES2335557T3 (es) | 1997-01-21 | 2010-03-29 | Sanofi Pasteur | Conjugados de peptido-polisacarido. |
US5925628A (en) | 1997-03-31 | 1999-07-20 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5912239A (en) | 1997-04-04 | 1999-06-15 | Genzyme Corporation | Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5948925A (en) | 1997-05-06 | 1999-09-07 | Genzyme Corporation | Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids |
US5952516A (en) | 1997-05-08 | 1999-09-14 | Genzyme Corporation | Cationic amphiphiles containing multiplesteroid lipophilic groups |
US5942634A (en) | 1997-05-09 | 1999-08-24 | Genzyme Corporation | Cationic amphiphiles for cell transfections |
DE69835367T2 (de) | 1997-10-29 | 2007-08-02 | Genzyme Corp., Framingham | Gentherapie für gaucher-krankheit |
SE513149C2 (sv) | 1997-12-05 | 2000-07-17 | Katarina Edwards | Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna |
US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
US6703488B1 (en) | 1998-01-15 | 2004-03-09 | Center For Molecular Medicine And Immunology | Antibody/receptor targeting moiety for enhanced delivery of armed ligand |
US6287857B1 (en) | 1998-02-09 | 2001-09-11 | Genzyme Corporation | Nucleic acid delivery vehicles |
AU750972B2 (en) | 1998-02-17 | 2002-08-01 | Genzyme Corporation | Methods for purified AAV vector production |
JP2002538758A (ja) | 1998-02-17 | 2002-11-19 | ジェンザイム・コーポレイション | 偽アデノウイルスベクターの製造方法 |
US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
WO1999057296A1 (en) | 1998-05-01 | 1999-11-11 | Genzyme Corporation | Partially deleted adenoviral vectors |
US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
US6538117B1 (en) | 1999-08-10 | 2003-03-25 | The Scripps Research Institute | Programmable one-pot oligosaccharide synthesis |
US6399575B1 (en) | 1998-11-10 | 2002-06-04 | Auburn University | Methods and compositions for targeting compounds to the central nervous system |
US6610703B1 (en) | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
GB0100889D0 (en) | 2001-01-12 | 2001-02-21 | Oxford Glycosciences Uk Ltd | Compounds |
GB9909066D0 (en) | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
GB9909064D0 (en) | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
EP1196190B1 (en) | 1999-07-26 | 2003-03-19 | G.D. SEARLE & CO. | Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of a medicament for the treatment of glycolipid storage diseases |
US6770468B1 (en) | 1999-09-14 | 2004-08-03 | Genzyme Glycobiology Research Institute, Inc. | Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway |
US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
WO2001036620A2 (en) | 1999-11-16 | 2001-05-25 | Genzyme Corporation | Vectors and transgenies with regulatory elements for gene delivery to the liver |
US6749865B2 (en) | 2000-02-15 | 2004-06-15 | Genzyme Corporation | Modification of biopolymers for improved drug delivery |
AU2001238346A1 (en) | 2000-02-15 | 2001-08-27 | Genzyme Corporation | Modification of biopolymers for improved drug delivery |
WO2001060377A2 (en) | 2000-02-17 | 2001-08-23 | Genzyme Corporation | Methods for treatment of lysosomal storage diseases using biphosphonates |
CA2441903C (en) | 2000-05-26 | 2012-07-31 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
US20040014652A1 (en) | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
AU2001269923A1 (en) | 2000-06-19 | 2002-01-02 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
AU2001280035A1 (en) | 2000-07-26 | 2002-02-05 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Intracellular delivery system for protein phosphatases and other polypeptides |
EP1315559B1 (en) | 2000-08-18 | 2006-03-22 | Massachusetts Institute Of Technology | Apparatus and methods for the automated synthesis of oligosaccharides |
US6676963B1 (en) | 2000-10-27 | 2004-01-13 | Barnes-Jewish Hospital | Ligand-targeted emulsions carrying bioactive agents |
US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
US7001994B2 (en) | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
ES2300439T3 (es) | 2001-04-30 | 2008-06-16 | Zystor Therapeutics , Inc. | Reconocimiento subcelular de proteinas terapeuticas. |
US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
EP1385873A2 (en) | 2001-05-07 | 2004-02-04 | Supratek Pharma, Inc. | A ligand for enhancing oral and cns delivery of biological agents |
JP5038582B2 (ja) | 2001-07-16 | 2012-10-03 | ジェンザイム・コーポレーション | Udp−グルコース:n−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成 |
ES2516041T3 (es) | 2001-10-10 | 2014-10-30 | Ratiopharm Gmbh | Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH) |
US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
WO2003045928A1 (en) | 2001-11-26 | 2003-06-05 | Genzyme Corporation | Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors |
DE60228492D1 (de) * | 2001-11-28 | 2008-10-02 | Neose Technologies Inc | Remodellierung von glycoproteinen unter verwendung von endoglycanasen |
US6905856B2 (en) | 2001-12-21 | 2005-06-14 | Genzyme Glycobiology Research Institute, Inc. | Soluble GlcNAc phosphotransferase |
US6800472B2 (en) | 2001-12-21 | 2004-10-05 | Genzyme Glycobiology Research Institute, Inc. | Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase |
JP2006506317A (ja) | 2002-01-11 | 2006-02-23 | バイオマリン ファーマシューティカル インコーポレイテッド | 治療用リソソーム酵素の送達のための酵素送達系としてのp97の使用 |
AU2003219796A1 (en) | 2002-02-20 | 2003-09-09 | Beth Israel Deaconess Medical Center | Conjugates comprising a biodegradable polymer and uses therefor |
US6916802B2 (en) | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
SI2332567T1 (sl) | 2003-01-31 | 2015-08-31 | The Mount Sinai School Of Medicine Of New York University | Kombinirana terapija za zdravljenje motenj pomanjkanja proteina |
US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
EP1638605B1 (en) | 2003-06-20 | 2014-01-08 | Raptor Pharmaceutical, Inc. | Delivery of therapeutic compounds to the brain and other tissues |
JP2007501811A (ja) | 2003-08-08 | 2007-02-01 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。 |
US7691826B2 (en) | 2003-08-12 | 2010-04-06 | Lipoxen Technologies Limited | Polysialic acid derivatives |
US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
US7232805B2 (en) | 2003-09-10 | 2007-06-19 | Inflabloc Pharmaceuticals, Inc. | Cobalamin conjugates for anti-tumor therapy |
EP1525890A1 (en) | 2003-10-02 | 2005-04-27 | Complex Biosystems GmbH | Protein-Proteophore complexes |
US7176185B2 (en) | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
EP1713508A2 (en) | 2004-01-29 | 2006-10-25 | Biosynexus Incorporated | Use of amino-oxy functional groups in the preparation of vaccine conjugates |
WO2005077093A2 (en) | 2004-02-06 | 2005-08-25 | Biomarin Pharmaceutical Inc. | Manufacture of highly phosphorylated lysosomal enzymes and uses thereof |
EP1740204B1 (en) | 2004-04-01 | 2018-03-14 | Chiesi Farmaceutici S.p.A. | Medicinal use of alpha-mannosidase |
US8017151B2 (en) | 2004-09-07 | 2011-09-13 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Amphiphilic polymer-protein conjugates and methods of use thereof |
WO2006108052A2 (en) | 2005-04-06 | 2006-10-12 | Genzyme Corporation | Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting |
AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
WO2008029281A2 (en) * | 2006-02-10 | 2008-03-13 | Invitrogen Corporation | Labeling and detection of post translationally modified proteins |
WO2008089339A2 (en) * | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharide conjugates for cellular targeting |
DK2457920T3 (en) | 2007-01-18 | 2018-01-22 | Genzyme Corp | Oligosaccharides comprising an amino oxy group and conjugates thereof |
EP3608330B1 (en) * | 2008-12-16 | 2022-11-09 | Genzyme Corporation | Synthetic intermediates for preparing oligosaccharide-protein conjugates |
-
2009
- 2009-12-11 EP EP19167964.6A patent/EP3608330B1/en active Active
- 2009-12-11 HU HUE14194176 patent/HUE044381T2/hu unknown
- 2009-12-11 CA CA2747230A patent/CA2747230C/en not_active Expired - Fee Related
- 2009-12-11 PT PT121600092T patent/PT2465542E/pt unknown
- 2009-12-11 PL PL12160009T patent/PL2465542T3/pl unknown
- 2009-12-11 BR BRPI0923047A patent/BRPI0923047B8/pt active IP Right Grant
- 2009-12-11 JP JP2011542288A patent/JP5658167B2/ja active Active
- 2009-12-11 SI SI200931162T patent/SI2465542T1/sl unknown
- 2009-12-11 WO PCT/US2009/067775 patent/WO2010075010A2/en active Application Filing
- 2009-12-11 DK DK12160009.2T patent/DK2465542T3/en active
- 2009-12-11 CN CN2013103303923A patent/CN103432566A/zh not_active Withdrawn
- 2009-12-11 CN CN202011052459.8A patent/CN112220930A/zh active Pending
- 2009-12-11 BR BR122020010601A patent/BR122020010601B8/pt active IP Right Grant
- 2009-12-11 DK DK19167964.6T patent/DK3608330T3/da active
- 2009-12-11 CN CN201610298866.4A patent/CN105879047A/zh active Pending
- 2009-12-11 ES ES12160009.2T patent/ES2534056T3/es active Active
- 2009-12-11 EP EP22205652.5A patent/EP4212541A1/en active Pending
- 2009-12-11 EP EP12160009.2A patent/EP2465542B1/en active Active
- 2009-12-11 EP EP09771640A patent/EP2376123A2/en not_active Withdrawn
- 2009-12-11 EP EP14194176.5A patent/EP2889043B1/en active Active
- 2009-12-11 CA CA3040973A patent/CA3040973A1/en not_active Abandoned
- 2009-12-11 CN CN202011434866.5A patent/CN112618724A/zh active Pending
- 2009-12-11 SI SI200931981T patent/SI2889043T1/sl unknown
- 2009-12-11 LT LTEP14194176.5T patent/LT2889043T/lt unknown
- 2009-12-11 ES ES14194176T patent/ES2735023T3/es active Active
- 2009-12-11 PT PT14194176T patent/PT2889043T/pt unknown
- 2009-12-11 ES ES19167964T patent/ES2937017T3/es active Active
- 2009-12-11 DK DK14194176.5T patent/DK2889043T3/da active
- 2009-12-11 CN CN200980156896XA patent/CN102369023A/zh active Pending
- 2009-12-11 MX MX2015002855A patent/MX364498B/es unknown
- 2009-12-11 US US13/140,272 patent/US8835614B2/en active Active
- 2009-12-11 MX MX2011006347A patent/MX2011006347A/es active IP Right Grant
- 2009-12-11 PL PL14194176T patent/PL2889043T3/pl unknown
- 2009-12-11 HU HUE19167964A patent/HUE060974T2/hu unknown
- 2009-12-11 TR TR2019/09909T patent/TR201909909T4/tr unknown
-
2011
- 2011-06-14 MX MX2019004905A patent/MX2019004905A/es unknown
- 2011-06-16 IL IL213595A patent/IL213595B/en active IP Right Grant
-
2012
- 2012-12-07 HK HK12112646.9A patent/HK1171697A1/xx unknown
-
2014
- 2014-03-07 JP JP2014045356A patent/JP2014139204A/ja not_active Withdrawn
- 2014-07-29 US US14/445,941 patent/US9493498B2/en active Active
-
2015
- 2015-03-25 IL IL237932A patent/IL237932B/en active IP Right Grant
- 2015-03-25 HR HRP20150340TT patent/HRP20150340T1/hr unknown
- 2015-03-25 IL IL237933A patent/IL237933A0/en unknown
- 2015-03-30 SM SM201500082T patent/SMT201500082B/xx unknown
- 2015-11-11 HK HK15111147.2A patent/HK1210413A1/xx unknown
-
2016
- 2016-09-20 JP JP2016182748A patent/JP6659503B2/ja active Active
- 2016-10-07 US US15/288,486 patent/US10464962B2/en active Active
-
2019
- 2019-03-13 JP JP2019046041A patent/JP2019112444A/ja not_active Withdrawn
- 2019-06-18 HR HRP20191102TT patent/HRP20191102T1/hr unknown
- 2019-07-10 CY CY20191100730T patent/CY1121860T1/el unknown
- 2019-09-24 US US16/581,148 patent/US11279725B2/en active Active
- 2019-11-26 IL IL270930A patent/IL270930B/en unknown
-
2021
- 2021-06-20 IL IL284184A patent/IL284184B2/en unknown
- 2021-07-02 JP JP2021110649A patent/JP2021169467A/ja active Pending
-
2022
- 2022-02-14 US US17/671,249 patent/US20220242899A1/en active Pending
-
2023
- 2023-08-24 JP JP2023136066A patent/JP2023164869A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019004905A (es) | Conjugados de oligosacaridos-proteinas. | |
CY1122452T1 (el) | Ολιγοσακχαριτες που περιλαμβανουν μια ομαδα αμινοοξυ- και συζευγματα αυτων | |
MX2010003977A (es) | Terapia de combinacion con conjugados de anticuerpo-farmaco. | |
MX349749B (es) | Suministro enzimatico intraventricular para enfermedades de almacenamiento lisosomico. | |
IN2012DN04908A (es) | ||
EP2170054A4 (en) | TARGETING CONJUGATES WITH ACTIVE SUBSTANCES ENCAPLED IN CYCLODEXTRIN POLYMERS | |
MX2018013333A (es) | Composiciones de nucleasas terapeuticas y metodos. | |
MX2018013332A (es) | Conjugados de pirrolobenzodiazepina diana. | |
MX2010004488A (es) | Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas. | |
EP2506881C0 (en) | COMBINATION OF RADIOIMMUNOTHERAPY AND ANTIBODY-DRUG CONJUGATES FOR IMPROVED CANCER THERAPY | |
WO2010059253A3 (en) | Methods and compositions for localized agent delivery | |
EP2346896A4 (en) | CONJUGATES OF ETOPOSIDE AND DOXORUBICIN FOR THE ADMINISTRATION OF MEDICAMENTS | |
MX2009013982A (es) | Composiciones que comprenden inhibidores de triptofano hidroxilasa. | |
MX2010004110A (es) | Formulacion para mejorar la funcion gastrointestinal. | |
AR061155A1 (es) | Preparaciones liofilizadas de pantoprazol sodico para inyeccion | |
BRPI0917819B8 (pt) | compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado | |
CY1116394T1 (el) | Συζευγματα ολιγοσακχαριτη-πρωτεϊνης | |
MX2010006170A (es) | Composicion farmaceutica para la limpieza del intestino. | |
CY1114320T1 (el) | Ολιγοσακχαριτες που περιλαμβανουν αμινοοξυ-ομαδα και συζευγματα αυτων | |
IL202849A0 (en) | Targeting conjugates comprising active agent encapsulated in cyclodextrin-containing polymers | |
TR201819137T4 (tr) | Terapötik nükleaz bileşimleri ve yöntemler. | |
SI2121713T1 (sl) | Oligosaharidi, ki obsegajo aminooksi skupino, in njihovi konjugati |